| HOME >> BIOLOGY >> TECHNOLOGY |
Amortization of intangible and capital assets
Amortization of intangible assets in the first quarter of fiscal 2009 totaled $3,000 (2008 - $7,000). Amortization of capital assets in the first quarter of fiscal 2009 totaled $64,000 (2008 - $66,000).
Stock-based compensation
Stock-based compensation expense in the first quarter of fiscal 2009 totaled $nil (2008 - $12,000). The stock-based compensation expense in the first quarter of fiscal 2008 relates to the ongoing amortization of compensation costs of stock options granted on June 30, 2005, over their vesting period.
Interest income
Interest income in the first quarter of fiscal 2009 totaled $205,000 (2008 - $104,000) and is mainly the result of higher cash balances.
Foreign exchange loss
Foreign exchange losses in the first quarter of fiscal 2009 totaled $150,000 (2008 - $108,000). Foreign exchange losses are mainly the result of the foreign currency translation of the Company's integrated foreign operation in Ireland. The net assets in Ireland consist mainly of cash and cash equivalents, denominated in Euro dollars, which are used to fund clinical trials of Topical Interferon Alpha-2b in Europe. In addition, U.S. dollar purchases of inventory for distribution in Canada also contributed to the foreign exchange loss.
Income taxes
Income tax expense in the first quarter of fiscal 2009 totaled $30,000 (2008 - $32,000). All income taxes are attributable to the Company's operations in Ireland.
cash flow
Operating activities
N
'/>"/>
| SOURCE Helix BioPharma Corp. Copyright©2008 PR Newswire. All rights reserved |